Back to Results
First PageMeta Content
Bristol-Myers Squibb / Cetuximab / Tyrosine kinase receptors / Immune system / Symphogen / Monoclonal antibody therapy / Monoclonal antibodies / HER2/neu / Zalutumumab / Immunology / Biology / Medicine


Advancing the Frontier of Antibody Therapeutics Kirsten Drejer, PhD Chief Executive Officer
Add to Reading List

Document Date: 2014-01-14 13:28:11

Open Document

File Size: 1,82 MB

Share Result on Facebook

Company

Merck KGaA / Genentech / Novo A/S / PhD / /

Country

Japan / /

Currency

EUR / /

Event

FDA Phase / /

IndustryTerm

Cancer Treatment / oncology product / drug product / reproducible single batch manufacturing process / /

MedicalCondition

tumor / truly innovative multi-target antibody mixture products Tumor / Cancer / NSCLC / Angiogenesis Tumor / /

MedicalTreatment

chemo / /

Person

Symphogen / Antibody Therapeutics Kirsten Drejer / /

Position

Chief Executive Officer / /

Product

Erbitux / Japan / /

SocialTag